Genentech, Inc. et al v. Sanofi-Aventis Deutschland GMBH et al, No. 3:2008cv04909 - Document 622 (N.D. Cal. 2011)
Court Description: Final JUDGMENT and Certification pursuant to Federal Rule of Civil Procedure 54(b) (SI, COURT STAFF) (Filed on 4/21/2011) Modified on 4/21/2011 (ys, COURT STAFF).
Download PDF
<![CDATA[
Genentech, Inc. et al v. Sanofi-Aventis Deutschland GMBH et al Doc. 622 1 2 3 4 5 IN THE UNITED STATES DISTRICT COURT 6 FOR THE NORTHERN DISTRICT OF CALIFORNIA 7 8 GENENTECH, INC., et al., 9 United States District Court For the Northern District of California 10 11 12 No. C 08-4909 SI; No. C 09-4919 SI Plaintiffs, FINAL JUDGMENT AND CERTIFICATION PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 54(b) v. SANOFI-AVENTIS DEUTSCHLAND GMBH, Defendant. / 13 14 Finding that there is no just reason for delay, and pursuant to Federal Rule of Civil Procedure 15 54(b), the Court enters final judgment of non-infringement of the patents-in-suit as to Rituxan® and 16 Avastin® in favor of Genentech and Biogen Idec. and against Sanofi-Aventis Deutschland GMBH. 17 This is a final, appealable judgment. 18 19 IT IS SO ORDERED AND ADJUDGED. 20 21 22 Dated: April 21, 2011 SUSAN ILLSTON United States District Judge 23 24 25 26 27 28 Dockets.Justia.com
]]>
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You
should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
